ReviewCurrent medicinal chemistry2026
Mechanisms and Characteristics of Chronic Pain in Alzheimer's Disease: A Narrative Review.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pain in Alzheimer's Disease: Disrupted Multilevel Integration of Nociception, Affective Processing and Clinical Expression Across Clinical and Preclinical Evidence.Life (Basel, Switzerland) · 2026Review
- Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Meta analysis of glucose metabolism across Alzheimer's, Parkinson's and ALS Reveals emergence of adaptive brain glucometabolic responses and associated neurological functional profiles.medRxiv : the preprint server for health sciences · 2026Article
- Advances in Medicinal Chemistry: From Cancer to Chronic Diseases (Part I).Current medicinal chemistry · 2026Article
- Multi-regional transcriptomic analysis reveals early nociceptive and neuroinflammatory alterations in APP/PS1 mice.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is a neurodegenerative illness that significantly diminishes patients' quality of life. Chronic pain remains a major contributor to exacerbating patients' well-being. This comprehensive review aims to explore the mechanisms underlying pain perception in AD as well as identify potential targets and future considerations for pain relief. AD causes structural and functional alterations in the affected brain, including shrinkage of gray matter volume and disruptions in brain network connectivity. Besides memory loss, pain is a significant yet often neglected symptom. Effective pain management in AD is challenged by the adverse effects of pain-relief medications and communication difficulties, especially as the disease progresses. Both non- and pharmacological interventions are currently used to alleviate pain in AD. Pharmacological options include opioids, nonsteroidal anti-inflammatory drugs, paracetamol/acetaminophen, and adjuvant pain relievers like antidepressants and antiepileptic medications, though these are not officially approved for pain relief in AD. Non-pharmacological strategies, such as exercise therapy, music therapy, Reiki, reflexology, and behavioral therapy, are preferred to prevent the side effects of medication. However, the use of these methods is limited due to a lack of high-quality research. The review highlights a crucial link between neurological changes in AD and the perception of pain, underscoring the need for customized pain management approaches for this population. Emphasizing non-pharmacological interventions could potentially improve pain management in AD patients, provided that further research supports their effectiveness.
Indexed as
Identifiers
40237049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.